(Q37783417)

23 August 2017

title

Progress toward novel treatments for chronic kidney disease (English)

1 reference

23 August 2017

Progress Toward Novel Treatments for Chronic Kidney Disease (English)

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

2 July 2024

author name string

Sudhir V. Shah

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20797560

2 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20797560

2 July 2024

publication date

1 September 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S1051227610001524?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

https://api.elsevier.com/content/article/PII:S1051227610001524?httpAccept=text/plain

2 July 2024

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Journal of Renal Nutrition

2 July 2024

published in

1 reference

23 August 2017

volume

20

1 reference

23 August 2017

issue

5 Suppl

1 reference

23 August 2017

page(s)

S122-6

1 reference

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Aliskiren combined with losartan in type 2 diabetes and nephropathy

2 July 2024

2

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

2 July 2024

3

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

2 July 2024

4

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Novel therapies of diabetic nephropathy

2 July 2024

5

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria

2 July 2024

6

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease

2 July 2024

7

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

2 July 2024

8

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Pirfenidone is renoprotective in diabetic kidney disease

2 July 2024

9

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

2 July 2024

10

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.

2 July 2024

11

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.

2 July 2024

12

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Bicarbonate supplementation slows progression of CKD and improves nutritional status

2 July 2024

13

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

2 July 2024

14

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Role of free radicals and catalytic metal ions in human disease: an overview

2 July 2024

15

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Oxidants in chronic kidney disease

2 July 2024

16

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

Cytochrome P-450 as a source of catalytic iron in minimal change nephrotic syndrome in rats

2 July 2024

17

1 reference

https://api.crossref.org/works/10.1053/J.JRN.2010.06.013

2 July 2024

Identifiers

1 reference

23 August 2017

1 reference